Post-trial follow-up | Efficacy and safety of first-line lorlatinib vs. crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

Original Study: First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer – New England Journal of Medicine

Commentary on Twitter

NEW—Updated, long-term data from the CROWN study show durable benefit of lorlatinib vs crizotinib in pts w/ treatment-naive, ALK-positive #NSCLC

From Prof Benjamin Solomon & colleagues https://t.co/jfOEMRNEgl pic.twitter.com/SBaRCBEGIy

— The Lancet Respiratory Medicine (@LancetRespirMed) December 19, 2022